Irisin: A messenger from the gods?;Irisina: ¿transmisor de mensajes del Olimpo?

Clinica e Investigacion en Arteriosclerosis

Volumn 26, Issue 3, 2014, Pages 140-146

  Moreno, María ^a   Moreno Navarrete, José María ^a   Fernández Real, José Manuel ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Adipose tissue; Cytokines; Irisin; Physical activity

Indexed keywords

CYTOKINE; IRISIN; UNCLASSIFIED DRUG; FIBRONECTIN; FNDC5 PROTEIN, HUMAN;

PROTEIN FUNCTION; SHORT SURVEY; THERMOGENESIS; WHITE ADIPOSE TISSUE; ADIPOCYTE; ANIMAL; EXERCISE; HUMAN; METABOLISM; PHYSIOLOGY; SKELETAL MUSCLE;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; EXERCISE; FIBRONECTINS; HUMANS; MUSCLE, SKELETAL;

EID: 84902388252     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2013.11.002     Document Type: Short Survey

References (41)

1. Thompson D., Karpe F., Lafontan M., Frayn K. Physical activity and exercise in the regulation of human adipose tissue physiology. Physiol Rev 2012, 92:157-191.
2. Schmidt M., Johannesdottir S.A., Lemeshow S., Lash T.L., Ulrichsen S.P., Bøtker H.E., et al. Cognitive test scores in young men and subsequent risk of type 2 diabetes, cardiovascular morbidity, and death. Epidemiology 2013, 24:632-636.
3. Ladenheim E.E. Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control. Curr Opin Endocrinol Diabetes Obes 2012, 19:13-18.
4. Trujillo M.E., Scherer P.E. Adipose tissue-derived factors: Impact on health and disease. Endocr Rev 2006, 27:762-778.
5. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: Skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012, 8:457-465.
6. Van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., Drossaerts J.M., Kemerink G.J., Bouvy N.D., et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009, 360:1500-1508.
7. Wu J., Boström P., Sparks L.M., Ye L., Choi J.H., Giang A.H., et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012, 150:366-376.
8. Seale P., Bjork B., Yang W., Kajimura S., Chin S., Kuang S., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008, 454(7207):961-967.
9. Baar K., Wende A.R., Jones T.E., Marison M., Nolte L.A., Chen M., et al. Adaptations of skeletal muscle to exercise: Rapid increase in the transcriptional coactivator PGC-1. FASEB J 2002, 16:1879-1886.
10. Boström P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012, 481(7382):463-468.
11. Shan T., Liang X., Bi P., Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle. FASEB J 2013, 27:1981-1989.
12. Huang Z., Chen X., Chen D. Myostatin: A novel insight into its role in metabolism, signal pathways, and expression regulation. Cell Signal 2011, 23:1441-1446.
13. Roca-Rivada A., Castelao C., Senin L.L., Landrove M.O., Baltar J., Belén Crujeiras A., et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 2013, 8:e60563.
14. Sáinz N., Rodríguez A., Catalán V., Becerril S., Ramírez B., Lancha A., et al. Leptin reduces the expression and increases the phosphorylation of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4 in muscle of ob/ob mice. PLoS One 2012, 7:e29389.
15. Moon H.S., Dalamaga M., Kim S.Y., Polyzos S.A., Hamnvik O.P., Magkos F., et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 2013, 34:377-412.
16. Roberts M.D., Bayless D.S., Company J.M., Jenkins N.T., Padilla J., Childs T.E., et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 2013, 62:1052-1056.
17. Dun S.L., Lyu R.M., Chen Y.H., Chang J.K., Luo J.J., Dun N.J. Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience 2013, 240:155-162.
18. Ivanov I.P., Firth A.E., Michel A.M., Atkins J.F., Baranov P.V. Identification of evolutionarily conserved non-AUG-initiated N-terminal extensions in human coding sequences. Nucleic Acids Res 2011, 39:4220-4234.
19. Raschke S., Elsen M., Gassenhuber H., Sommerfeld M., Schwahn U., Brockmann B., et al. Evidence against a beneficial effect of irisin in humans. PLoS One 2013, 8:e73680.
20. Timmons J.A., Baar K., Davidsen P.K., Atherton P.J. Is irisin a human exercise gene?. Nature 2012, 488(7413):E9-E10.
21. Huh J.Y., Panagiotou G., Mougios V., Brinkoetter M., Vamvini M.T., Schneider B.E., et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma, and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012, 61:1725-1738.
22. Moraes C., Leal V.O., Marinho S.M., Barroso S.G., Rocha G.S., Boaventura G.T., et al. Resistance exercise training does not affect plasma irisin levels of hemodialysis patients. Horm Metab Res 2013, 45:900-904.
23. Pekkala S., Wiklund P., Hulmi J.J., Ahtiainen J.P., Horttanainen M., Pöllänen E., et al. Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health?. J Physiol 2013, 591(Pt 21):5393-5400.
24. Rodgers J.T., Lerin C., Gerhart-Hines Z., Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 2008, 582:46-53.
25. Vamvini M.T., Aronis K.N., Panagiotou G., Huh J.Y., Chamberland J.P., Brinkoetter M.T., et al. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol 2013, 169:829-834.
26. Sánchez J., Nozhenko Y., Palou A., Rodríguez A.M. Free fatty acid effects on myokine production in combination with exercise mimetics. Mol Nutr Food Res 2013, 57:1456-1467.
27. Lecker S.H., Zavin A., Cao P., Arena R., Allsup K., Daniels K.M., et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail 2012, 5:812-818.
28. Buchman A.S., Boyle P.A., Yu L., Shah R.C., Wilson R.S., Bennett D.A. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 2012, 78:1323-1329.
29. Moon H.S., Dincer F., Mantzoros C.S. Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism 2013, 62:1131-1136.
30. Vanitallie T.B. Preclinical sporadic Alzheimer's disease: Target for personalized diagnosis and preventive intervention. Metabolism 2013, 62(Suppl 1):S30-S33.
31. Moreno-Navarrete J.M., Ortega F., Serrano M., Guerra E., Pardo G., Tinahones F., et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013, 98:E769-E778.
32. Ibrahim M.M. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes Rev 2010, 11:11-18.
33. Choi Y.K., Kim M.K., Bae K.H., Seo H.A., Jeong J.Y., Lee W.K., et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013, 100:96-101.
34. Liu J.J., Wong M.D., Toy W.C., Tan C.S., Liu S., Ng X.W., et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013, 27:365-369.
35. Staiger H., Böhm A., Scheler M., Berti L., Machann J., Schick F., et al. Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived 'browning' factor irisin, determines insulin sensitivity. PLoS One 2013, 8:e61903.
36. Park K.H., Zaichenko L., Brinkoetter M., Thakkar B., Sahin-Efe A., Joung K.E., et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013, 10.1210/jc.2013-2373.
37. Stengel A., Hofmann T., Goebel-Stengel M., Elbelt U., Kobelt P., Klapp B.F. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index. Peptides 2013, 39:125-130.
38. Zhang H.J., Zhang X.F., Ma Z.M., Pan L.L., Chen Z., Han H.W., et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013, 59:557-562.
39. Wen M.S., Wang C.Y., Lin S.L., Hung K.C. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013, 8:e64025.
40. Gouni-Berthold I., Berthold H.K., Huh J.Y., Berman R., Spenrath N., Krone W., et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 2013, 8:e72858.
41. Aydin S., Kuloglu T., Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides 2013, 47:66-70.